Business Segment Information Business Segment Information (Tables)

3 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Segment Reporting [Table Text Block]

The following table compares business segment revenues and business segment and Corporate operating income for the three months ended June 30, 2026 and 2025:

Three Months Ended June 30, 2026
(in millions)	Healthcare		AST		Life Sciences		Corporate		Company
Revenues	$	1,048.3	$	297.6	$	146.7	$	—	$	1,492.7
Segment expenses
Cost of revenues	589.1		140.1		66.0
Selling, general, and administrative	173.9		14.0		16.4
Research and development	25.1		0.6		2.5
Total income from operations before adjustments	$	260.2	$	142.9	$	61.8	$	(110.1)	$	354.8
Less: Adjustments
Amortization of acquired intangible assets (1)									65.3
Acquisition and integration related charges (2)									1.5
Tax restructuring costs (3)									0.3
Amortization of inventory and property "step up" to fair value (1)									1.8
Total income from operations									$	285.8

Three Months Ended June 30, 2025
(in millions)	Healthcare		AST		Life Sciences		Corporate		Company
Revenues	$	974.7	$	281.2	$	135.2	$	—	$	1,391.1
Segment expenses
Cost of revenues	557.4		129.9		58.0
Selling, general, and administrative	159.1		13.7		16.0
Research and development	22.7		0.9		2.4
Total income from operations before adjustments	$	235.5	$	136.7	$	58.7	$	(114.0)	$	316.9
Less: Adjustments
Amortization of acquired intangible assets (1)									67.1
Acquisition and integration related charges (2)									0.5
Tax restructuring costs (3)									0.2
Amortization of inventory and property "step up" to fair value (1)									1.4
Restructuring charges (4)									1.8
Total income from operations									$	246.0

(1) For more information regarding our recent acquisitions, refer to Note 3 titled, "Business Acquisitions."

(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

(3) Costs incurred in tax restructuring.

(4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring."

(in millions)	June 30, 2026		March 31, 2026
Assets
Healthcare and Life Sciences	$	7,141.9	$	7,146.8
AST	3,594.2		3,590.4
Total assets	$	10,736.1	$	10,737.2

	Three Months Ended June 30,
(in millions)	2026		2025
Capital Expenditures
Healthcare and Life Sciences	$	42.2	$	44.4
AST	45.3		49.2
Total Capital Expenditures	$	87.5	$	93.6
Depreciation, Depletion, and Amortization
Healthcare and Life Sciences	$	81.0	$	83.1
AST	42.7		36.3
Total Depreciation, Depletion, and Amortization	$	123.8	$	119.4

(in millions)	June 30, 2026		March 31, 2026
Property, Plant, and Equipment, Net
Ireland	$	87.6	$	88.1
United States	1,110.9		1,094.4
Other locations	973.2		978.7
Property, Plant, and Equipment, Net	$	2,171.7	$	2,161.2

Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block]

	Three Months Ended June 30,
(in millions)	2026		2025
Revenues:
Ireland	$	29.0	$	22.5
United States	1,090.6		1,025.6
Other locations	373.2		342.9
Total Revenues	$	1,492.7	$	1,391.1

Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block]

Additional information regarding our fiscal 2027 and fiscal 2026 revenue is disclosed in the following table:

	Three Months Ended June 30,
(in millions)	2026		2025
Healthcare:
Capital equipment	$	230.5	$	227.3
Consumables	391.9		358.9
Service	425.9		388.5
Total Healthcare Revenues	$	1,048.3	$	974.7
AST:
Capital equipment	$	1.4	$	1.6
Service	296.3		279.6
Total AST Revenues	$	297.6	$	281.2
Life Sciences:
Capital equipment	$	31.3	$	26.6
Consumables	81.5		75.3
Service	34.0		33.3
Total Life Sciences Revenues	$	146.7	$	135.2
Total Revenues	$	1,492.7	$	1,391.1